EXEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EXEL is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has bullish price action, improving fundamentals, strong Q1 growth, supportive analyst target increases, and constructive options sentiment. With no negative insider or congress activity and no AI Stock Picker/SwingMax trigger, it is still attractive as a straightforward long-term buy at the current pre-market price of 46.25.
EXEL is in a bullish trend. MACD histogram is positive and expanding, RSI_6 at 55.764 is neutral-to-bullish, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Current pre-market price of 46.25 is just above the pivot at 45.835 and below resistance at 47.905, which suggests the stock is holding trend support and has room to test higher levels. The short-term pattern outlook also points to modest upside over the next week and month.
["Q1 revenue grew 9.97% YoY to about $610.8M", "Net income grew 31.86% YoY and EPS grew 43.64% YoY", "CABOMETYX TRx market share improved from 44% to 47% in Q1 2026", "Company repurchased about $430.8M of stock in Q1 and approved a new $750M repurchase plan", "ZANZA CRC NDA remains a major catalyst with PDUFA expected in early December 2026", "Analysts have been raising price targets across multiple firms"]
["Some analysts remain cautious, with Hold and Equal Weight ratings still present", "TD Cowen noted the ZANZA story still needs to prove itself after prior cabo failures", "RBC previously highlighted competitive pressure from Merck in the HIF-2alpha space", "No AI Stock Picker or SwingMax signal is active today"]
Latest quarter: Q1 2026. Financials were strong and improving across the board. Revenue increased to $610.8M, up 9.97% YoY; net income rose to $210.5M, up 31.86% YoY; EPS increased to $0.79, up 43.64% YoY; gross margin remained very high at 96.73%. This shows solid operating leverage and continued earnings strength.
Analyst sentiment has trended more positive recently. H.C. Wainwright raised its target to $56 and kept Buy, TD Cowen raised to $55 and kept Buy, Morgan Stanley raised to $50 with Equal Weight, Stifel raised to $47 with Hold, and Barclays raised to $45 with Equal Weight. The overall Wall Street view is mixed but improving, with the bullish camp pushing targets higher while neutral ratings still reflect some caution around pipeline execution and competitive risk. No recent politician or congress trading activity was reported, and hedge fund/insider trends were neutral.
